153 related articles for article (PubMed ID: 38233781)
21. Association between the Preoperative Dietary Antioxidant Index and Postoperative Quality of Life in Patients with Esophageal Squamous Cell Carcinoma: A Prospective Study Based on the TTD Model.
Zhang J; Zhou J; Huang Y; Lin Z; Zhang S; Qiu M; Xiang Z; Hu Z
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447155
[TBL] [Abstract][Full Text] [Related]
22. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
23. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Garon EB; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; Robinet G; Le Moulec S; Natale R; Schneider J; Shepherd FA; Garassino MC; Geater SL; Szekely ZP; Van Ngoc T; Liu F; Scheuring U; Patel N; Peters S; Rizvi NA
Clin Lung Cancer; 2021 Jul; 22(4):301-312.e8. PubMed ID: 33775558
[TBL] [Abstract][Full Text] [Related]
24. Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
Lu Z; Kong L; Wang B; Wang J; Liu L; Shu Y; Yang L; Sun G; Cao G; Ji Y; Cui T; Liu H; Qiu W; Li N; Li G; Luo H; Hou X; Zhang Y; Yue W; Xue L; Liu Z; Pan Y; Gao S; Wang X; Pan Z; Zhang S; Lin G; Xie Y; Gu K; Ren T; Li W; Li T; Wang S; He W; Fan Y; Liang J; Xia B; Zhao L; Wang S; Shen L
EClinicalMedicine; 2024 Jun; 72():102623. PubMed ID: 38800802
[TBL] [Abstract][Full Text] [Related]
25. Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study.
Aggarwal J; Chakraborty S; Ghosh Laskar S; Patil VM; Prabhash K; Bhattacharya A; Noronha V; Purandare NC; Joshi A; Mummudi N; Arora J; Badhe R
Cureus; 2017 Apr; 9(4):e1149. PubMed ID: 28497011
[TBL] [Abstract][Full Text] [Related]
26. Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
Sommer K; Cottone F; Aaronson NK; Fayers P; Fazi P; Rosti G; Angelucci E; Gaidano G; Venditti A; Voso MT; Baccarani M; Vignetti M; Efficace F
Qual Life Res; 2020 Mar; 29(3):815-823. PubMed ID: 31782016
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
28. Impact of response shift on time to deterioration in quality of life scores in breast cancer patients.
Hamidou Z; Dabakuyo-Yonli TS; Guillemin F; Conroy T; Velten M; Jolly D; Causeret S; Graesslin O; Gauthier M; Mercier M; Bonnetain F
PLoS One; 2014; 9(5):e96848. PubMed ID: 24828426
[TBL] [Abstract][Full Text] [Related]
29. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
[TBL] [Abstract][Full Text] [Related]
30. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population.
Pilz MJ; Loth FLC; Nolte S; Thurner AMM; Gamper EM; Anota A; Liegl G; Giesinger JM;
J Patient Rep Outcomes; 2024 May; 8(1):48. PubMed ID: 38695992
[TBL] [Abstract][Full Text] [Related]
31. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
32. Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.
El Alami Y; Essangri H; Majbar MA; Boutayeb S; Benamr S; El Malki HO; Souadka A
BMC Cancer; 2021 Jan; 21(1):99. PubMed ID: 33499819
[TBL] [Abstract][Full Text] [Related]
33. Updated normative data for the EORTC QLQ-C30 in the general Dutch population by age and sex: a cross-sectional panel research study.
de Ligt KM; Aaronson NK; Liegl G; Nolte S;
Qual Life Res; 2023 Sep; 32(9):2477-2487. PubMed ID: 37031427
[TBL] [Abstract][Full Text] [Related]
34. An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study.
Koyi H; Brandén E; Gnarpe J; Gnarpe H; Steen B
APMIS; 2001 Sep; 109(9):572-80. PubMed ID: 11878709
[TBL] [Abstract][Full Text] [Related]
35. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.
Koller M; Hjermstad MJ; Tomaszewski KA; Tomaszewska IM; Hornslien K; Harle A; Arraras JI; Morag O; Pompili C; Ioannidis G; Georgiou M; Navarra C; Chie WC; Johnson CD; Himpel A; Schulz C; Bohrer T; Janssens A; Kuliś D; Bottomley A
Ann Oncol; 2017 Nov; 28(11):2874-2881. PubMed ID: 28945875
[TBL] [Abstract][Full Text] [Related]
36. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
[TBL] [Abstract][Full Text] [Related]
37. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
38. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
[TBL] [Abstract][Full Text] [Related]
39. Impact of pre-radiation therapy quality of life in lung cancer survival: a prospective, intention-to-treat, multicenter study.
Nieto-Guerrero Gómez JM; Silva Vega GP; Cacicedo J; Delgado León BD; Herrero Rivera D; Praena Fernández JM; Rivin Del Campo E; Ortiz Gordillo MJ; López Guerra JL
Clin Transl Oncol; 2020 Sep; 22(9):1635-1644. PubMed ID: 32072471
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires.
Ficko SL; Pejsa V; Zadnik V
Radiol Oncol; 2019 Sep; 53(3):337-347. PubMed ID: 31553711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
